shutterstock_1505189714_estherpoon
estherpoon / Shutterstock.com
1 December 2022FeaturesPharmaRebecca Anderson-Smith

Exhaustion and parallel trade: what’s next for pharma TMs?

Ever since the UK announced its intended departure from the European Union (EU), there has been much speculation about whether and how the UK would amend its trademark exhaustion and parallel trade regime. Following the recent UK government consultation, the position has become clearer, although the government has not ruled out the possibility of making further changes in the future.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Pharma
9 July 2026   Separate lawsuits target Indian and Taiwanese pharma companies as Exelixis seeks to keep rival cabozantinib products off the US market until key patents expire.
Pharma
7 July 2026   Leading women from the pharmaceutical and biotechnology sectors are among the more than 100 professionals recognised in a newly released Influential Women in IP 2026 list, which celebrates leadership, expertise and innovation.
Pharma
1 July 2026   Otsuka v Sun Pharma could redefine which pharmaceutical patents qualify for patent term extensions, with major implications for innovator companies, generic manufacturers and the future of market exclusivity in the country.